Although the experimental evidence showing a functional role for the IGF-II/IRA both in embryonal fibroblasts and in cancer has been available since the late 90a, these findings did not seem to affect the rush of drug developers to bring IGF-IR specific blockers to clinical trials. Here, IGF2 is linked to cancer.